Prevalence of ciprofloxacin‐resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK
- 25 March 2015
- journal article
- Published by Wiley in BJU International
- Vol. 116 (1) , 131-134
Abstract
Objective: To determine the efficacy of fluoroquinolone prophylaxis in patients undergoing transrectal ultrasonography ( TRUS )‐guided biopsy of the prostate in the N orwich population, and its correlation with ciprofloxacin resistance in the faecal flora. We also aimed to determine the usefulness of a pre‐biopsy rectal screen for resistant bacteria in these patients. Patients and Methods: The incidence and microbiology of sepsis after TRUS ‐guided prostate biopsies between 2007 and 2011 was audited retrospectively. Subsequently, in 2012, a prospective study was performed, collecting the same data but also culturing rectal swabs from all patients undergoing TRUS ‐guided biopsy, with a post‐biopsy follow‐up period of 6 months. All patients were given prophylactic oral ciprofloxacin, as per Trust policy (750 mg 1 h before biopsy, followed by 250 mg twice daily for 3 subsequent days). Results: Between 2007 and 2011, 3600 patients underwent TRUS ‐guided biopsy. Among these, 11 (0.3%) were admitted to hospital for post‐biopsy related sepsis but only 4 (0.1%) had ciprofloxacin‐resistant E scherichia coli confirmed from blood cultures: three had ciprofloxacin‐susceptible Enterobacteriaceae, and four had no ciprofloxacin susceptibility data. In 2012, 10 (3.7%) of 267 patients sampled before biopsy had ciprofloxacin‐resistant E . coli recovered on rectal swab culture but none of these men presented with post‐biopsy sepsis; during the 6‐month follow‐up period, seven patients were diagnosed with urinary tract infections. Conclusion: Ciprofloxacin‐resistant Enterobacteriaceae remains rare in the intestinal flora of the N orwich TRUS population, meaning that the drug remains adequate as prophylaxis. Pre‐biopsy rectal swabs may be useful for individual departments to periodically assess their own populations and to ensure their antibiotic policy remains valid. In populations where resistance is known to be highly prevalent, pre‐biopsy rectal swabs can help guide addition of further antibiotics to prevent post‐biopsy septicaemia.Keywords
This publication has 21 references indexed in Scilit:
- Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized TrialEuropean Urology, 2012
- High community faecal carriage rates of CTX-M ESBL-producing Escherichia coli in a specific population group in Birmingham, UKJournal of Antimicrobial Chemotherapy, 2012
- Rectal Cultures Before Transrectal Ultrasound-guided Prostate Biopsy Reduce Post-prostatic Biopsy Infection RatesUrology, 2012
- Adding amikacin to fluoroquinolone‐based antimicrobial prophylaxis reduces prostate biopsy infection ratesBJU International, 2010
- Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsyBJU International, 2010
- Changing antibiotic prophylaxis for transrectal ultrasound‐guided prostate biopsies: are we putting our patients at risk?BJU International, 2010
- INFECTIONS AFTER PROSTATE BIOPSY AND ANTIBIOTIC RESISTANCEBJU International, 2008
- A Large Outbreak ofClostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone UseInfection Control & Hospital Epidemiology, 2005
- Antibiotic resistance of faecal Escherichia coli from healthy volunteers from eight developing countriesJournal of Antimicrobial Chemotherapy, 2004
- Antibiotic Prophylaxis in Ultrasound Guided Transrectal Prostate BiopsyJournal of Urology, 1997